Skip to content
Recovery & Performance PeptidesRecovery research and practical context
Recovery article

BPC-157 5mg Dosage Protocol | PeptideDosages.com

BPC-157 (5 mg Vial) Dosage Protocol BPC-157 Dosage Chart BPC-157 is dosed at 200 mcg–600 mcg daily via subcutaneous injection in educational protocols. A 5 mg vial reconstituted with bacteriostatic water yields about 1.67 mg/mL. This information is for researc

By Recovery & Performance Peptides Editorial Team

BPC-157 (5 mg Vial) Dosage Protocol

BPC-157 Dosage Chart

BPC-157 is dosed at 200 mcg–600 mcg daily via subcutaneous injection in educational protocols. A 5 mg vial reconstituted with bacteriostatic water yields about 1.67 mg/mL. This information is for research and educational use only.

Reconstitute: Add 3.0 mL bacteriostatic water → 1.67 mg/mL concentration.

Typical daily range: 200–600 mcg once daily (gradual titration).

Easy measuring: At 1.67 mg/mL, 1 unit = 0.01 mL ≈ 16.7 mcg on a U-100 insulin syringe.

Storage: Lyophilized: freeze at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F); avoid freeze–thaw cycles.

BPC-157 (Body Protection Compound-157) is a synthetic 15-amino-acid peptide derived from a gastric protein sequence studied for tissue-healing and cytoprotective properties[1][2]. Preclinical models demonstrate accelerated wound repair and anti-inflammatory activity[3], though human clinical data remain limited to early-phase safety trials and small case reports[4][5]. This educational protocol presents a once-daily subcutaneous approach using a practical dilution for clear insulin-syringe measurements.

Research context: For evidence on mechanisms, human and preclinical research, limitations, and safety, read BPC-157 Peptide: Benefits, Uses, Side Effects, Dosage, and Research.

Standard / Gradual Approach (3 mL = ~1.67 mg/mL)

Route: Subcutaneous | Frequency: Once daily

Weeks 1–2

200 mcg (0.2 mg)

12 units (0.12 mL)

Weeks 3–4

400 mcg (0.4 mg)

24 units (0.24 mL)

Weeks 5–8+

600 mcg (0.6 mg)

36 units (0.36 mL)

Frequency: Inject once daily subcutaneously. This schedule uses the largest practical dilution (3.0 mL) to keep per-injection units well above 10 for better accuracy. Dosing is extrapolated from preclinical models[1][6]; human clinical validation remains limited.

Reconstitution Steps

Draw 3.0 mL bacteriostatic water with a sterile syringe.

Inject slowly down the vial wall; avoid foaming.

Gently swirl/roll until dissolved (do not shake).

Label and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.

Supplies Needed

Plan based on an 8–16 week daily protocol with gradual titration.

Peptide Vials (BPC-157, 5 mg each):

8 weeks ≈ 6 vials (25.2 mg used)

12 weeks ≈ 9 vials (42 mg used)

16 weeks ≈ 12 vials (58.8 mg used)

Insulin Syringes (U-100):

Per week: 7 syringes (1/day)

8 weeks: 56 syringes

12 weeks: 84 syringes

16 weeks: 112 syringes

Bacteriostatic Water (10 mL bottles): Use ~3.0 mL per vial for reconstitution.

8 weeks (6 vials): 18 mL → 2 × 10 mL bottles

12 weeks (9 vials): 27 mL → 3 × 10 mL bottles

16 weeks (12 vials): 36 mL → 4 × 10 mL bottles

Alcohol Swabs: One for the vial stopper + one for the injection site each day.

Per week: 14 swabs (2/day)

8 weeks: 112 swabs → recommend 2 × 100-count boxes

12 weeks: 168 swabs → recommend 2 × 100-count boxes

16 weeks: 224 swabs → recommend 3 × 100-count boxes

CONNECTED / MODULES

Post-session references

Selected from shared article topics. Source links are retained where available.

01

Handling & safety lane

Source-derived education, not individual medical guidance or an instruction to dose.

DOSAGE SOURCE

Protocol Variables That Modify BPC-157 LL-37 Synergy Dosing Timing

Injection site proximity to the injury determines how much timing precision matters. Subcutaneous injection within 5cm of the target tissue (e.g., injecting near the Achilles for tendon repair) allows both peptides to reach the injury via local diffusion and lymphatic drainage. Timing windows tighten because peptides arrive faster. Injecting farther from the injury (e.g., abdominal subcutaneous for systemic delivery) extends the time to peak effect at the target, which can stretch the optimal interval to 90–120 minutes. Intramuscular injection accelerates absorption. BPC-157 IM reaches peak plasma concentration 20–30 minutes faster than subcutaneous, shortening the ideal interval to 45–60 minutes. Reconstitution and storage affect peptide stability and, indirectly, timing reliability. Both BPC-157 and LL-37 are supplied as lyophilised powders and reconstituted with bacteriostatic water. Once reconstituted, BPC-157 remains stable for 28 days at 2–8°C; LL-37 degrades more rapidly, maintaining full potency for approximately 14 days under refrigeration. If LL-37 has been reconstituted for more than two weeks, effective concentration may be 10–20% lower than labelled, requiring dose adjustment or shortening the interval to compensate for reduced peptide availability. Our team recommends reconstituting LL-37 in smaller batches (e.g., 2mg vials rather than 5mg) to minimise waste from degradation. Concurrent use of other peptides or growth factors can shift timing windows. If combin…
STORAGE

Storage & Handling

Before Reconstitution Room temp or refrigerated. Keep away from light. After Reconstitution Refrigerate at 2 – 8°C (standard fridge) Shelf Life 28 days once reconstituted Never Freeze reconstituted peptide. Expose to direct sunlight. Use past 28 days.
02

Question drills

Open a question for its connected answer.

01What If Researchers Want to Source BPC-157 for Preclinical Studies — What Purity Standards Apply?+

Research-grade BPC-157 must meet minimum 98% purity verified by HPLC (high-performance liquid chromatography) with mass spectrometry confirmation of the correct 15-amino-acid sequence. Reputable suppliers provide Certificates of Analysis (CoA) documenting purity, endotoxin levels below 1 EU/mg, and absence of bacterial contamination. Peptides synthesised via solid-phase peptide synthesis (SPPS) using Fmoc chemistry are standard. Crude synthesis yields 60–70% purity, requiring multiple purification steps to reach research-grade specifications. Real Peptides manufactures every batch through small-batch synthesis with exact amino-acid sequencing, guaranteeing purity and lab reliability for institutions conducting BPC-157 studied fibromyalgia research protocols.

SOURCE / realpeptides.co ↗
02What If I'm Considering BPC-157 as an Add-On to My Current Biologic Therapy?+

Consult your prescribing gastroenterologist before introducing any research compound alongside biologics like infliximab or vedolizumab. BPC-157's angiogenic effects could theoretically complement immune suppression by addressing the structural repair gap, but no interaction studies exist to confirm safety or efficacy in combination. The peptide's influence on VEGF signaling might alter drug pharmacokinetics, and dosing without medical oversight introduces risk of immune modulation you can't monitor at home.

SOURCE / realpeptides.co ↗
03What If My Vial Has Been Sitting Out for a Week?+

Discard it and order a replacement. A vial left at room temperature for seven days has likely degraded beyond salvage. Even if it looks clear and sterile. Oxidative breakdown doesn't change the solution's appearance, but it destroys the peptide's tertiary structure and receptor-binding capacity. Injecting degraded peptide won't harm you in most cases, but it won't deliver therapeutic effect either. That's $50–$80 wasted on an expensive saline injection.

SOURCE / realpeptides.co ↗
04What If I Want to Stack BPC-157 with Other Recovery Peptides?+

BPC-157 combines safely with TB-500, MK 677, or oral collagen peptides because each targets different mechanisms. BPC-157 upregulates VEGF and angiogenesis, TB-500 modulates actin and inflammation, MK 677 elevates systemic GH and IGF-1, and collagen provides substrate amino acids. Inject BPC-157 and TB-500 separately (different injection sites) to prevent peptide interaction in the syringe. Time MK 677 dosing in the evening to align with natural GH pulse timing. Avoid stacking with compounds that suppress immune function (corticosteroids, NSAIDs at high doses) during the first 7–10 days of injury recovery. BPC-157's benefits depend on intact inflammatory signalling.

SOURCE / realpeptides.co ↗
05What If I Have an Active H. Pylori Infection?+

BPC-157 is not an antimicrobial—it won't eradicate H. pylori bacteria. What it may do: accelerate healing of ulcers caused by the infection once antibiotic therapy (clarithromycin + amoxicillin + PPI) clears the bacteria. A 2021 study in Life Sciences tested this scenario in infected rodents and found BPC-157 reduced post-eradication ulcer persistence by 50%. The takeaway: it's potentially adjunctive to standard triple therapy, not a replacement.

SOURCE / realpeptides.co ↗
03

Evidence cooldown

Research context and source excerpts for a slower second read.

RESEARCH

Research Handling Note:

For best results in a research setting, allow both the peptide and chosen solvent to reach ambient laboratory temperature before reconstitution. This helps maintain structural integrity during dissolution. *Reconstitution solutions are supplied separately. Stock: 38142 Model: BPC-157 5mg Molecular Formula: C62H98N16O22 SKU: BPC5-024 Research Only: Yes

RESEARCH

The Clinical Truth About BPC-157 ARA-290 Protocol Neuropathy Research

Here's the honest answer: most patients starting peptide therapy for neuropathy expect complete symptom resolution, and that expectation is unrealistic. BPC-157 ara-290 protocol neuropathy research shows that these compounds support nerve repair and reduce inflammatory pain. They don't reverse neuropathy that has progressed to complete fiber loss. If nerve conduction studies show severe axonal degeneration with no measurable response, peptides won't restore function. They work best in early-to-moderate neuropathy (grade 1–2) where damaged nerve fibers still exist and can regenerate. The second uncomfortable truth: most peptide suppliers sell underdosed or improperly stored compounds. ARA-290 in particular is expensive to synthesize correctly, and we've seen third-party testing show potency as low as 40% of labeled dose in some compounded preparations. If you're using a peptide protocol and see zero improvement by week 8, the peptide quality is suspect before assuming the protocol doesn't work. Real Peptides manufactures both BPC-157 and ARA-290 through small-batch synthesis with exact amino-acid sequencing and third-party purity verification. Because neuropathy protocols fail more often from dosing inconsistency than from mechanism failure. The timeline expectation matters too. Nerve regeneration occurs at approximately 1 mm per day in optimal conditions. If your neuropathy affects nerves 30–40 cm from the spinal cord (common in lower extremity diabetic neuropathy), structural recovery takes 12–16 weeks minimum. Stopping the protocol at week 6 because 'it isn't working' stops it before axonal regrowth has reached the affected tissue.

05

Product & matchup locker

Linked catalog and comparison files.

Comparison

BPC-157 Studied Stomach Ulcers: Human Use vs Research Evidence

The gap between BPC-157 studied stomach ulcers in preclinical models and its use in humans is significant. The peptide has no FDA approval for any indication. It is not classified…

Continue reading

Related articles

BPC-157 5mg

BPC-157 5mg Research Handling Note: For best results in a research setting, allow both the peptide and chosen solvent to reach ambient laboratory temperature before reconstitution. This helps maintain structural integri…

Read article